Kymera Therapeutics, Inc. (KYMR)
Largest Insider Buys in Sector
KYMR Stock Price History Chart
KYMR Stock Performance
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat …
Insider Activity of Kymera Therapeutics, Inc.
Over the last 12 months, insiders at Kymera Therapeutics, Inc. have bought $46 and sold $58.86M worth of Kymera Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Kymera Therapeutics, Inc. have bought $18.82M and sold $68.02M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP (director) — $696.
The last purchase of 1 shares for transaction amount of $46 was made by BAKER BROS. ADVISORS LP (director) on 2024‑08‑20.
List of Insider Buy and Sell Transactions, Kymera Therapeutics, Inc.
| 2024-09-17 | Sale | director | 13,500 0.0216% | $48.28 | $651,766 | -1.85% | ||
| 2024-08-26 | Sale | director | 5,000 0.0077% | $49.10 | $245,509 | -6.62% | ||
| 2024-08-20 | director | 1 <0.0001% | $46.41 | $46 | +0.03% | |||
| 2024-07-16 | Sale | Chief Medical Officer | 23,145 0.0578% | $45.81 | $1.06M | -4.78% | ||
| 2024-07-15 | Sale | Chief Medical Officer | 16,455 0.0405% | $45.15 | $742,925 | 0.00% | ||
| 2024-07-09 | Sale | director | 453,960 0.9459% | $38.21 | $17.35M | 0.00% | ||
| 2024-06-13 | Sale | director | 10,200 0.0168% | $34.98 | $356,796 | +31.78% | ||
| 2024-06-12 | Sale | director | 16,740 0.028% | $35.45 | $593,378 | +32.51% | ||
| 2024-06-07 | Sale | director | 8,500 0.0139% | $32.99 | $280,400 | +37.17% | ||
| 2024-05-23 | Sale | Chief Operating Officer | 2,575 0.0043% | $34.99 | $90,105 | +30.02% | ||
| 2024-03-15 | Sale | director | 71,764 0.1171% | $40.46 | $2.9M | -1.71% | ||
| 2024-03-14 | Sale | director | 55,779 0.0861% | $39.98 | $2.23M | +1.67% | ||
| 2024-03-13 | Sale | director | 139,255 0.2271% | $42.23 | $5.88M | -5.80% | ||
| 2024-03-13 | Sale | 10 percent owner | 139,255 0.2271% | $42.23 | $5.88M | -5.80% | ||
| 2024-03-12 | Sale | director | 162,918 0.2674% | $41.98 | $6.84M | -4.08% | ||
| 2024-03-12 | Sale | 10 percent owner | 162,918 0.2674% | $41.98 | $6.84M | -4.08% | ||
| 2024-03-11 | Sale | director | 51,184 0.0849% | $42.85 | $2.19M | -5.07% | ||
| 2024-03-11 | Sale | 10 percent owner | 51,184 0.0849% | $42.85 | $2.19M | -5.07% | ||
| 2024-03-04 | Sale | Chief Financial Officer | 3,934 0.0064% | $41.86 | $164,664 | -5.40% | ||
| 2024-03-04 | Sale | Chief Medical Officer | 3,344 0.0054% | $41.86 | $139,967 | -5.40% |
Insider Historical Profitability
| BAKER BROS. ADVISORS LP | director | 5516986 8.5184% | $48.81 | 1 | 0 | |
| BVF PARTNERS L P/IL | director | 2656191 4.1013% | $48.81 | 8 | 0 | <0.0001% |
| LAMPERT MARK N | 257754 0.398% | $48.81 | 4 | 0 | +55.88% |
Institutional Investor Ownership
| T. Rowe Price | $254.55M | 10.32 | 6.33M | +18.67% | +$40.05M | 0.03 | |
| Baker Bros Advisors LP | $241.04M | 9.77 | 6M | 0% | +$0 | 1.73 | |
| Atlas Venture Life Science Advisors Llc | $216.17M | 8.76 | 5.38M | -8.21% | -$19.33M | 20.06 | |
| Bvf Inc Il | $207.5M | 8.41 | 5.16M | 0% | +$0 | 1.52 | |
| The Vanguard Group | $191.64M | 7.77 | 4.77M | +19.25% | +$30.93M | <0.01 |